2.53

0.80% 0.02

After Hours: 2.53

Insight Molecular Diagnostics Inc (IMDX)

Overview News Price History Discussions Forecast

Insight Molecular Diagnostics Inc stock is traded at $2.53, with a volume of 15,240. It is up +0.80% in the last 24 hours and down -7.33% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Previous Close:

$2.51

Open:

$2.5098

24h Volume:

15,240

Relative Volume:

0.85

Market Cap:

$72.41M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-2.32%

1M Performance:

-7.33%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$2.33

$2.59

1-Week Range:

$2.33

$2.66

52-Week Range:

$2.33

$3.09

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name

Insight Molecular Diagnostics Inc

Sector

Healthcare (1145)

Industry

Diagnostics & Research (53)

Phone

949-409-7600

Address

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IMDX's Discussions on Twitter

Compare IMDX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMDX Insight Molecular Diagnostics Inc	2.53	71.84M	0	0	0	0.00
TMO Thermo Fisher Scientific Inc	492.72	184.93B	43.21B	6.58B	6.17B	17.29
DHR Danaher Corp	205.82	147.00B	24.01B	3.41B	4.86B	4.70
IDXX Idexx Laboratories Inc	647.09	51.77B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	125.66	35.50B	6.63B	1.17B	1.19B	4.05
IQV Iqvia Holdings Inc	190.81	32.08B	15.70B	1.24B	2.01B	6.91

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

Insight Molecular Diagnostics Inc Stock (IMDX) Latest News

Aug 26, 2025

iMDx to Participate in NYC Investment Conferences September 811 - GlobeNewswire

Aug 26, 2025

iMDx Announces Participation in NYC Investment Conferences - AInvest

Aug 26, 2025

Molecular Diagnostics Leader iMDx Announces Double-Header NYC Investor Conference Schedule for September - Stock Titan

Aug 26, 2025

Aug 25, 2025

iMDx CFO Andrea James discusses democratizing molecular diagnostics in podcast episode. - AInvest

Aug 25, 2025

IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics - MarketScreener

Aug 25, 2025

Aug 23, 2025

HIV Diagnostics Market Size, Share & Forecast, 2025–2034 - Global Market Insights Inc.

Aug 23, 2025

Aug 19, 2025

Insight Molecular Diagnostics: Pioneering the Next Generation of Transplant Rejection Testing and FDA Readiness - AInvest

Aug 19, 2025

Veterinary Molecular Diagnostics Market on Track for Massive Expansion by 2035, Forecasts Reveal. - newstrail.com

Aug 19, 2025

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 19, 2025

Aug 18, 2025

Insight Molecular Diagnostics Inc. shares rise 12.92% intraday after Myriad Genetics appoints new CFO. - AInvest

Aug 18, 2025

Molecular Diagnostics Market Evolving Rapidly from 2025 to 2032 | F. Hoffmann-La Roche Ltd, Illumina, Inc. - openPR.com

Aug 18, 2025

Insight Molecular: Needham Reiterates Buy Rating with $4.25 PT - AInvest

Aug 18, 2025

Aug 15, 2025

Insight Molecular Diagnostics: Paving the Next Frontier in Transplant Rejection Testing with FDA-Ready Innovation - AInvest

Aug 15, 2025

IMDX’s GraftAssureDx Study: A Game-Changer in Kidney Transplant Monitoring? - TipRanks

Aug 15, 2025

Insight Molecular Diagnostics Inc. shares rise 1.21% intraday after Caris Life Sciences validates MI Cancer Seek® assay. - AInvest

Aug 15, 2025

Aug 14, 2025

Insight Molecular Diagnostics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Aug 14, 2025

Aug 13, 2025

Insight Molecular Diagnostics : With Q&A (insight molecular diagnostics inc imdx us q2 2025 earnings call 11 august 2025 5 00 pm et) - MarketScreener

Aug 13, 2025

Lake Street Sticks to Their Buy Rating for Insight Molecular Diagnostics (IMDX) - The Globe and Mail

Aug 13, 2025

Aug 12, 2025

Insight Molecular Diagnostics Inc. shares fall 1.53% intraday after reporting a Q2 loss of $9.7 million. - AInvest

Aug 12, 2025